Imipenem/Cilastatin/Relebactam

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, Evopoint Biosciences Inc., Hartford Hospital

Conditions

Cystic FibrosisHematopoietic and Lymphoid Cell NeoplasmHospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial PneumoniaMalignant Solid NeoplasmPneumonia, Bacterial

Phase 2

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

CompletedNCT04983901

M.D. Anderson Cancer CenterHematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm

Start: 2021-09-14End: 2023-10-06Updated: 2024-11-04

Phase 3

Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

CompletedNCT05204563

Evopoint Biosciences Inc.Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

Start: 2022-07-31End: 2024-09-29Updated: 2025-11-06

Phase 4

Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

TerminatedNCT05561764

Hartford HospitalCystic Fibrosis, Pneumonia, Bacterial

Start: 2023-01-03End: 2024-12-11Updated: 2024-12-17

Related Papers

Procalcitonin Level Monitoring in Antibiotic De-Escalation and Stewardship Program for Patients with Cancer and Febrile Neutropenia

Cancers2024-10-115 citations